Przejdź do zawartości
Merck

Endogenous glutamine decrease is associated with pancreatic cancer progression.

Oncotarget (2017-12-10)
Cecilia Roux, Chiara Riganti, Sammy Ferri Borgogno, Roberta Curto, Claudia Curcio, Valeria Catanzaro, Giuseppe Digilio, Sergio Padovan, Maria Paola Puccinelli, Monica Isabello, Silvio Aime, Paola Cappello, Francesco Novelli
ABSTRAKT

Pancreatic ductal adenocarcinoma (PDAC) is becoming the second leading cause of cancer-related death in the Western world. The mortality is very high, which emphasizes the need to identify biomarkers for early detection. As glutamine metabolism alteration is a feature of PDAC, its

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Nα-Acetyl-L-glutamine